Cargando…
Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma pr...
Autores principales: | Missale, C., Losa, M., Boroni, F., Giovanelli, M., Balsari, A., Spano, P. F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034102/ https://www.ncbi.nlm.nih.gov/pubmed/8519650 |
Ejemplares similares
-
Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013) -
Temporal resolution of idiopathic granulomatous mastitis with resumption of bromocriptine therapy for prolactinoma
por: Bouton, Marcia E., et al.
Publicado: (2015) -
Recurrent Priapism From Cabergoline and Bromocriptine in a
Hypogonadal Man With Prolactinoma
por: Menon, Lakshmi P., et al.
Publicado: (2021) -
Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas
por: Xiao, Zhengzheng, et al.
Publicado: (2020) -
Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells
por: Huang, Jinxiang, et al.
Publicado: (2017)